Contrast developer Bracco Imaging is collaborating with longtime partner Shanghai Pharmaceuticals Holding in China on new R&D activities aimed at applying its ultrasound contrast agent technology for treatment monitoring in oncology.
Under the new strategic alliance, the firms said they will focus on using Bracco's microbubbles technology platform to support the development of new therapeutic drugs by Shanghai Pharmaceuticals. The combination of treatment monitoring capabilities from Bracco with a new immuno-oncology therapy by Shanghai Pharmaceuticals will address an unmet medical need in pancreatic cancer, said Bracco Imaging CEO Fulvio Renoldi Bracco in a statement.
Bracco first gained a direct presence in China via a joint venture in 2001 with Shanghai Sine, which is part of Shanghai Pharmaceuticals Group. That joint venture was extended for an additional 20 years at the end of 2016, Bracco said.
